These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29685883)

  • 21. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
    Mazieres J; Rittmeyer A; Gadgeel S; Hida T; Gandara DR; Cortinovis DL; Barlesi F; Yu W; Matheny C; Ballinger M; Park K
    J Thorac Oncol; 2021 Jan; 16(1):140-150. PubMed ID: 33166718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
    Bordoni R; Ciardiello F; von Pawel J; Cortinovis D; Karagiannis T; Ballinger M; Sandler A; Yu W; He P; Matheny C; Felizzi F; Rittmeyer A
    Clin Lung Cancer; 2018 Sep; 19(5):441-449.e4. PubMed ID: 30017645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
    Hopkins AM; Kichenadasse G; McKinnon RA; Rowland A; Sorich MJ
    Semin Oncol; 2019; 46(4-5):380-384. PubMed ID: 31735362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
    Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
    Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
    Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atezolizumab and Its Many Uses.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469902
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
    Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
    Pilotto S; Carbognin L; Rossi A; Tortora G; Bria E
    Semin Oncol; 2018 Jun; 45(3):176-180. PubMed ID: 30262399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
    Zhou K; Jiang C; Li Q
    Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
    Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
    Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
    Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
    Sridhar S; Paz-Ares L; Liu H; Shen K; Morehouse C; Rizvi N; Segal NH; Jin X; Zheng Y; Narwal R; Gupta A; Dennis PA; Ye J; Mukhopadhyay P; Higgs BW; Ranade K
    Clin Lung Cancer; 2019 Nov; 20(6):e601-e608. PubMed ID: 31327642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
    Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
    JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.